University of Iowa Holden Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of Iowa Holden Comprehensive Cancer Center

Dr. Milhem on the Utility of RP1 in Solid Tumors

February 25, 2022

Video

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors

January 19, 2022

Article

Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing immunotherapies to maximize antitumor response in anti–PD-1 refractory tumors.

Musculoskeletal Tumor Registry Collects QoL Data After Surgery in Sarcoma

February 21, 2020

Article

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field.